Suchergebnisse

Lectures delivered at the Winter School on Agroforestry for National Resource Sustainability, Livelihood Security and Climate Moderation, held at Jhansi during 4-24 February 2009

Context. Teegarden's Star is the brightest and one of the nearest ultra-cool dwarfs in the solar neighbourhood. For its late spectral type (M7.0 V), the star shows relatively little activity and is a prime target for near-infrared radial velocity surveys such as CARMENES. Aims. As part of the CARMENES search for exoplanets around M dwarfs, we obtained more than 200 radial-velocity measurements of Teegarden's Star and analysed them for planetary signals. Methods. We find periodic variability in the radial velocities of Teegarden's Star. We also studied photometric measurements to rule out stellar brightness variations mimicking planetary signals. Results. We find evidence for two planet candidates, each with 1.1 M minimum mass, orbiting at periods of 4.91 and 11.4 d, respectively. No evidence for planetary transits could be found in archival and follow-up photometry. Small photometric variability is suggestive of slow rotation and old age. Conclusions. The two planets are among the lowest-mass planets discovered so far, and they are the first Earth-mass planets around an ultra-cool dwarf for which the masses have been determined using radial velocities.© ESO 2019. ; M.Z. acknowledges support from the Deutsche Forschungsgemeinschaft under DFG RE 1664/12-1 and Research Unit FOR2544 >Blue Planets around Red Stars>, project no. RE 1664/14-1. CARMENES is an instrument for the Centro Astronomico Hispano-Aleman de Calar Alto (CAHA, Almeria, Spain). CARMENES is funded by the German Max-Planck-Gesellschaft (MPG), the Spanish Consejo Superior de Investigaciones Cientificas (CSIC), the European Union through FEDER/ERF FICTS-2011-02 funds, and the members of the CARMENES Consortium (Max-Planck-Institut fur Astronomie, Instituto de Astrofisica de Andalucia, Landessternwarte Konigstuhl, Institut de Ciencies de l'Espai, Institut fur Astrophysik Gottingen, Universidad Complutense de Madrid, Thuringer Landessternwarte Tautenburg, Instituto de Astrofisica de Canarias, Hamburger Sternwarte, Centro de Astrobiologia and Centro Astronomico Hispano-Aleman), with additional contributions by the Spanish Ministry of Economy, the German Science Foundation through the Major Research Instrumentation Programme and DFG Research Unit FOR2544 >Blue Planets around Red Stars>, the Klaus Tschira Stiftung, the states of Baden-Wurttemberg and Niedersachsen, and by the Junta de Andalucia. Based on data from the CARMENES data archive at CAB (INTA-CSIC). This article is based on observations made with the MuSCAT2 instrument, developed by ABC, at Telescopio Carlos Sanchez operated on the island of Tenerife by the IAC in the Spanish Observatorio del Teide. Data were partly collected with the 150-cm and 90-cm telescopes at the Sierra Nevada Observatory (SNO) operated by the Instituto de Astrofisica de Andalucia (IAA-CSIC). Data were partly obtained with the MONET/South telescope of the MOnitoring NEtwork of Telescopes, funded by the Alfried Krupp von Bohlen und Halbach Foundation, Essen, and operated by the Georg-August-Universitat Gottingen, the McDonald Observatory of the University of Texas at Austin, and the South African Astronomical Observatory. We acknowledge financial support from the Spanish Agencia Estatal de Investigacion of the Ministerio de Ciencia, Innovacion y Universidades and the European FEDER/ERF funds through projects AYA2015-69350-C3-2-P, AYA2016-79425-C3-1/2/3-P, AYA2018-84089, BES-2017-080769, BES-2017-082610, ESP2015-65712-C5-5-R, ESP2016-80435-C2-1/2-R, ESP2017-87143-R, ESP2017-87676-2-2, ESP2017-87676-C5-1/2/5-R, FPU15/01476, RYC-2012-09913, the Centre of Excellence >Severo Ochoa> and >Maria de Maeztu> awards to the Instituto de Astrofisica de Canarias (SEV-2015-0548), Instituto de Astrofisica de Andalucia (SEV-2017-0709), and Centro de Astrobiologia (MDM-2017-0737), the Generalitat de Catalunya through CERCA programme>, the Deutsches Zentrum fur Luft-und Raumfahrt through grants 50OW0204 and 50OO1501, the European Research Council through grant 6 94 513, the Italian Ministero dell'instruzione, dell'universita de della ricerca and Universita degli Studi di Roma Tor Vergata through FFABR 2017 and >Mission: Sustainability 2016>, the UK Science and Technology Facilities Council through grant ST/P000592/1, the Israel Science Foundation through grant 848/16, the Chilean CONICYT-FONDECYT through grant 31 80 405, the Mexican CONACYT through grant CVU 4 48 248, the JSPS KAKENHI through grants JP18H01265 and 18H05439, and the JST PRESTO through grant JPMJPR1775. ; Peer Reviewed

Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data.

Importance Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data. Objective To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning. Evidence Review We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence. Findings In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572 000 deaths and 15.2 million DALYs), and stomach cancer (542 000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819 000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601 000 deaths and 17.4 million DALYs), TBL cancer (596 000 deaths and 12.6 million DALYs), and colorectal cancer (414 000 deaths and 8.3 million DALYs). Conclusions and Relevance The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care.